FENC - Stock Analysis & Overview

About Fennec Pharmaceuticals Inc.

Biotechnology

Healthcare

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc. Key Metrics

Market Cap: $143M
52 Weeks Low: $5
52 Weeks High: $11.92
P/B: -105.02x
P/E: 53.53x
P/S: 2.91x

Upcoming Events

FENC Analyst Forecasts

‌

FENC Financials

FENC Income Statement Key Metrics

Revenue(TTM)49.04 M
Gross Profit(TTM)46.85 M
EBITDA(TTM)5.86 M
Net Income(TTM)2.66 M
EPS Diluted(TTM)0.03979999999999996

Decode FENC's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

FENC earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of FENC (0.941) is higher than the average of its peers (-0.392).

Net Profit Margin vs Peers

Net profit margin ratio of FENC (-0.755) is higher than the average of its peers (-75.925).

FENC Return on Equity

See how efficiently FENC generates profit for it's shareholders.

141.31%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of FENC (1.413) is higher than the average of its peers (-0.038).

Return on Equity Growth

FENC's Return on Equity has grown modestly over the past 10 years, increasing by only 8.80%.

FENC Revenue Growth

See how FENC has grown it's revenue over the past 10 years.

‌

Revenue Growth

FENC's revenue has grown significantly over the past 10 years, increasing by over 0%.

Fennec Pharmaceuticals Inc.

Page title

Section title